<DOC>
	<DOCNO>NCT01524926</DOCNO>
	<brief_summary>The study primarily assess antitumor activity crizotinib variety tumor alteration ALK and/or MET pathway . The targeted patient population include patient tumor harbor specific alteration lead ALK and/or MET activation , tyrosine kinase inhibitor target yet adequately explore .</brief_summary>
	<brief_title>CREATE : Cross-tumoral Phase 2 With Crizotinib</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Sarcoma , Clear Cell</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Alveolar</mesh_term>
	<mesh_term>Granuloma , Plasma Cell</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>General inclusion criterion : Locally advance and/or metastatic anaplastic large cell lymphoma Locally advance and/or metastatic inflammatory myofibroblastic tumor Locally advance and/or metastatic papillary renal cell carcinoma type 1 Locally advance and/or metastatic alveolar soft part sarcoma Locally advance and/or metastatic clear cell sarcoma Locally advance and/or metastatic alveolar rhabdomyosarcoma . The malignancy must incurable conventional surgery , radiotherapy , systemic therapy mean . Proven presence specific ALK and/or MET pathway alteration tumor tissue mandatory patient registration . Availability tumor material central pathology review Written inform consent Measurable disease accord RECIST 1.1 Patients brain metastasis eligible treated and/or neurologically stable ongoing requirement corticosteroid ( steroid least 2 week ) take contraindicated medication . Absence spinal cord compression unless treat patient attain good pain control stable recover neurologic function . No carcinomatous meningitis leptomeningeal disease . Any previous systemic anticancer therapy must complete least 4 week prior initiation study medication . No treatment investigational drug within past 4 week within less 4 halflife time investigational drug treatment crizotinib ( whatever long period ) . No prior therapy directly target ALK and/or MET , previous treatment crizotinib . Major surgery must complete least 4 week prior initiation study medication . Prior palliative radiotherapy must complete least 24 hrs prior initiation study medication , minor surgical procedure must complete least two week prior initiation study medication . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 , Lansky play scale ≥ 50 child age 1 12 yo Adequate hematological function : ANC ≥ 1 x 109/L , platelet ≥ 30 x 109/L hemoglobin ≥ 8 g/dL . Adequate bone marrow , renal hepatic function All related adverse event previous therapy must recover ≤ Grade 1 ( except alopecia ) . No persistence adverse event prior anticancer therapy deem clinically relevant . No acute chronic severe gastrointestinal condition diarrhea ulceration . Normal cardiac function cerebrovascular accident include transient ischemic attack . No current congestive heart failure . No ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; 2 . No uncontrolled atrial fibrillation grade . QTc interval &lt; 470 msec . Absence interstitial lung disease . No concurrent use drug food know strongCYP3A4 inhibitor No concurrent use drug know potent CYP3A4 inducer , within 12 day prior first dose crizotinib No concomitant intercurrent illness Effective contraception method ( applicable ) Diseasespecific inclusion criterion patient anaplastic large cell lymphoma Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advance advanced disease . Patient must receive previous systemic chemotherapy ( usually CHOPlike multidrug combination , medically contraindicate , without monoclonal antibody ) , may qualify conventional therapy curative intent . No pretreatment limitation ( include autologous allogeneic stem cell bone marrow transplantation ) , provide patient selection criterion meet . Diseasespecific inclusion criterion patient inflammatory myofibroblastic tumor Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advanced metastatic disease . No mandatory pretreatment . No pretreatment limitation , provide patient selection criterion meet . Diseasespecific inclusion criterion patient papillary renal cell carcinoma type 1 Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advanced metastatic disease . No mandatory pretreatment . No pretreatment limitation , provide patient selection criterion meet . Diseasespecific inclusion criterion patient clear cell sarcoma Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advanced metastatic disease . No mandatory pretreatment . No pretreatment limitation , provide patient selection criterion meet . Diseasespecific inclusion criterion patient alveolar soft part sarcoma Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advanced metastatic disease . No mandatory pretreatment . No pretreatment limitation , provide patient selection criterion meet . Diseasespecific inclusion criterion patient alveolar rhabdomyosarcoma Patient may receive previous systemic treatment , surgery and/or radiotherapy localize , locally advanced metastatic disease . Patient must receive previous systemic chemotherapy ( usually anthracyclinebased , medically contraindicate ) , may qualify conventional therapy curative intent . No pretreatment limitation , provide patient selection criterion meet .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>Anaplastic large cell lymphoma</keyword>
	<keyword>Inflammatory myofibroblastic tumor</keyword>
	<keyword>Papillary renal cell carcinoma type 1</keyword>
	<keyword>Alveolar soft part sarcoma</keyword>
	<keyword>Clear cell sarcoma</keyword>
	<keyword>Alveolar rhabdomyosarcoma</keyword>
</DOC>